Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 2/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 4/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21125091 | 0.99 | OXTR (0.52) | OXTRLDHABAZ2BMLNRAVPR1A | |
| SCHEMBL18573165 | 0.90 | OXTR (0.56) | OXTRLDHABAZ2BMLNRAVPR1A | |
| SCHEMBL21397870 | 0.89 | OXTR (0.45) | OXTRLDHABAZ2BMLNRAVPR1A | |
| SCHEMBL18573410 | 0.89 | OXTR (0.43) | OXTRLDHABAZ2BMLNRAVPR1A | |
| SCHEMBL21721909 | 0.86 | ABL1 (0.43) | OXTRMLNRATMPTPN2PTPN1 | |
| SCHEMBL22059448 | 0.84 | OXTR (0.51) | OXTRLDHABAZ2BMLNRAVPR1A | |
| SCHEMBL19933593 | 0.84 | OXTR (0.51) | OXTRLDHABAZ2BMLNRATM | |
| SCHEMBL23018754 | 0.84 | OXTR (0.40) | OXTRLDHABAZ2BMLNRAVPR1A | |
| SCHEMBL20007063 | 0.83 | OXTR (0.41) | OXTRLDHABAZ2BMLNRAVPR1A | |
| SCHEMBL22059897 | 0.82 | GPBAR1 (0.41) | OXTRMLNRHSD17B2HSD17B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507294-B1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2021-02-24 | — | — | EP | disclosed |
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | MERCK PATENT GMBH | 2021-01-12 | — | — | US | disclosed |
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2019-07-04 | — | — | US | disclosed |
| WO-2018041769-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | PARN, PUF60, PARG | OXTR 1526/4885LDHA 2820/4885BAZ2B 596/4885 |
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | PARN, PUF60, PARG | OXTR 1526/4885LDHA 2820/4885BAZ2B 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.